Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · OPKO HEALTH, INC. (OPK)

OPKO Health Q3 revenue rises 16% to $65.4 million; Labcorp sale agreed

Mixed Impact 4 of 5 earnings Written later

OPKO Health reported third-quarter 2026 revenue from continuing operations of $65.4 million, up 16% from $56.4 million a year earlier, and a narrower operating loss of $31.4 million. The net loss from continuing operations per share widened to $0.05 from $0.04, and the company withdrew its services revenue and total costs guidance because of the pending sale of its BioReference diagnostic operations to Labcorp.

Key points

  • Q3 2026 revenue from continuing operations rose 16% to $65.4 million; operating loss narrowed to $31.4 million from $33.6 million.
  • Net loss from continuing operations was $35.5 million, or $0.05 per share, versus $33.0 million, or $0.04 per share, a year earlier.
  • Agreement with Labcorp provides $722 million in cash at closing plus up to $150 million in additional consideration over up to ten years; closing requires regulatory approvals.
  • Services revenue guidance withdrawn; company issued Q4 2026 product revenue guidance of $41.0 million to $46.0 million and full-year total revenue guidance of $268.0 million to $278.0 million.

The filing

CompanyOPKO HEALTH, INC. (OPK)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:24 PM ET
Accession number0001193125-26-447357

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.